Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge
HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with so...
Gespeichert in:
Veröffentlicht in: | Proceedings of the National Academy of Sciences - PNAS 1999-09, Vol.96 (19), p.10842-10847 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 10847 |
---|---|
container_issue | 19 |
container_start_page | 10842 |
container_title | Proceedings of the National Academy of Sciences - PNAS |
container_volume | 96 |
creator | Cohen, Sandra S. Li, Chiang Ding, Linna Cao, Yunzhen Pardee, Arthur B. Shevach, Ethan M. Cohen, David I. |
description | HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with soluble protein (sTat), and in seroconverting humans, and propose that Tat-induced suppression cripples immune surveillance to HIV infection. We show that macrophages are sensitive to sTat stimulation at concentrations 1,000-fold lower (500 pM) than T cells, and this stimulation is accompanied by the immunosuppressive induction of Fas ligand on the macrophage. T cell proliferative defects induced by sTat in vitro can be completely (at lower concentrations of sTat) or partially (at higher concentrations) reversed by antagonists to Fas/Fas ligand interaction. We further report a method to preserve immunogenicity while inactivating Tat immunosuppression through oxidation, which advances the use of oxidized Tat as a component of an anti-HIV vaccine. These observations define additional methods to study the immunosuppressive functions of sTat that now may be rapidly applied to primary isolates from individuals with differing clinical courses. Our findings have immediate relevance for vaccine development, by describing and supporting a strategy that includes inactivated sTat in a multicomponent, anti-HIV vaccine. |
doi_str_mv | 10.1073/pnas.96.19.10842 |
format | Article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_journals_201383561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>48840</jstor_id><sourcerecordid>48840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-2b203b738bbd6523fc434748d2fef5569728d35638652d0a4e99a93187ccc12d3</originalsourceid><addsrcrecordid>eNqFkc1v1DAUxC0EokvhjjhAxAFxyfL8kdiWuFQrYFcqgkPhajmO02aV2KntrOh_j7e7VC0HOFn2_Gbk9wahlxiWGDj9MDkdl7JeYpnvgpFHaIFB4rJmEh6jBQDhZX5mJ-hZjFsAkJWAp-gEAxOVxHSB1t-Dd352xrbFmZmTLTbjODsf52kKNsbeu6J3xa7f-eKrbXudMtjcFOvNz-JCp2J1pYfBukv7HD3p9BDti-N5in58_nSxWpfn375sVmfnpakISyVpCNCGU9E0bV0R2hlGGWeiJZ3tqqqWnIiWVjUVWW1BMyullhQLbozBpKWn6OMhd5qb0bbGuhT0oKbQjzrcKK979VBx_ZW69DuFueSQ7e-O9uCvZxuTGvto7DBoZ_0cFQdgTAj5XxBzBpzdJr79C9z6Obi8A0UAU5GHwRmCA2SCjzHY7u7DGNS-SrWvUslaYaluq8yW1_cHvWc4dJeBN0dgb_0jP4x4_29CdfMwJPsrZfTVAd3G5MMdm1fBgP4G6gi7Eg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201383561</pqid></control><display><type>article</type><title>Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Cohen, Sandra S. ; Li, Chiang ; Ding, Linna ; Cao, Yunzhen ; Pardee, Arthur B. ; Shevach, Ethan M. ; Cohen, David I.</creator><creatorcontrib>Cohen, Sandra S. ; Li, Chiang ; Ding, Linna ; Cao, Yunzhen ; Pardee, Arthur B. ; Shevach, Ethan M. ; Cohen, David I.</creatorcontrib><description>HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with soluble protein (sTat), and in seroconverting humans, and propose that Tat-induced suppression cripples immune surveillance to HIV infection. We show that macrophages are sensitive to sTat stimulation at concentrations 1,000-fold lower (500 pM) than T cells, and this stimulation is accompanied by the immunosuppressive induction of Fas ligand on the macrophage. T cell proliferative defects induced by sTat in vitro can be completely (at lower concentrations of sTat) or partially (at higher concentrations) reversed by antagonists to Fas/Fas ligand interaction. We further report a method to preserve immunogenicity while inactivating Tat immunosuppression through oxidation, which advances the use of oxidized Tat as a component of an anti-HIV vaccine. These observations define additional methods to study the immunosuppressive functions of sTat that now may be rapidly applied to primary isolates from individuals with differing clinical courses. Our findings have immediate relevance for vaccine development, by describing and supporting a strategy that includes inactivated sTat in a multicomponent, anti-HIV vaccine.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.96.19.10842</identifier><identifier>PMID: 10485913</identifier><language>eng</language><publisher>United States: National Academy of Sciences of the United States of America</publisher><subject>AIDS Vaccines - metabolism ; AIDS/HIV ; Animals ; Antibodies ; Antigens ; Biological Sciences ; Cells, Cultured ; Disease ; Dose-Response Relationship, Drug ; Fas antigen ; Fas Ligand Protein ; FasL protein ; Flow Cytometry ; Gene Products, tat - immunology ; Gene Products, tat - metabolism ; Gene Products, tat - pharmacology ; HIV ; HIV infections ; HIV Infections - immunology ; HIV Infections - metabolism ; Human immunodeficiency virus ; Humans ; Immune Tolerance - physiology ; Immunoblotting ; Immunology ; Immunosuppression ; Leukocytes, Mononuclear - immunology ; Leukocytes, Mononuclear - metabolism ; Macrophages - drug effects ; Macrophages - immunology ; Macrophages - metabolism ; Membrane Glycoproteins - antagonists & inhibitors ; Membrane Glycoproteins - metabolism ; Mice ; Mice, Inbred BALB C ; Monocytes ; Proteins ; Recombinant Proteins - pharmacology ; T lymphocytes ; T-Lymphocytes, Helper-Inducer - drug effects ; tat Gene Products, Human Immunodeficiency Virus ; Tetanus ; Vaccination ; Viruses</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 1999-09, Vol.96 (19), p.10842-10847</ispartof><rights>Copyright 1993-1999 The National Academy of Sciences of the United States of America</rights><rights>Copyright National Academy of Sciences Sep 14, 1999</rights><rights>Copyright © 1999, The National Academy of Sciences 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-2b203b738bbd6523fc434748d2fef5569728d35638652d0a4e99a93187ccc12d3</citedby><cites>FETCH-LOGICAL-c524t-2b203b738bbd6523fc434748d2fef5569728d35638652d0a4e99a93187ccc12d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.pnas.org/content/96/19.cover.gif</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/48840$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/48840$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,723,776,780,799,881,27903,27904,53769,53771,57995,58228</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10485913$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Sandra S.</creatorcontrib><creatorcontrib>Li, Chiang</creatorcontrib><creatorcontrib>Ding, Linna</creatorcontrib><creatorcontrib>Cao, Yunzhen</creatorcontrib><creatorcontrib>Pardee, Arthur B.</creatorcontrib><creatorcontrib>Shevach, Ethan M.</creatorcontrib><creatorcontrib>Cohen, David I.</creatorcontrib><title>Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with soluble protein (sTat), and in seroconverting humans, and propose that Tat-induced suppression cripples immune surveillance to HIV infection. We show that macrophages are sensitive to sTat stimulation at concentrations 1,000-fold lower (500 pM) than T cells, and this stimulation is accompanied by the immunosuppressive induction of Fas ligand on the macrophage. T cell proliferative defects induced by sTat in vitro can be completely (at lower concentrations of sTat) or partially (at higher concentrations) reversed by antagonists to Fas/Fas ligand interaction. We further report a method to preserve immunogenicity while inactivating Tat immunosuppression through oxidation, which advances the use of oxidized Tat as a component of an anti-HIV vaccine. These observations define additional methods to study the immunosuppressive functions of sTat that now may be rapidly applied to primary isolates from individuals with differing clinical courses. Our findings have immediate relevance for vaccine development, by describing and supporting a strategy that includes inactivated sTat in a multicomponent, anti-HIV vaccine.</description><subject>AIDS Vaccines - metabolism</subject><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Biological Sciences</subject><subject>Cells, Cultured</subject><subject>Disease</subject><subject>Dose-Response Relationship, Drug</subject><subject>Fas antigen</subject><subject>Fas Ligand Protein</subject><subject>FasL protein</subject><subject>Flow Cytometry</subject><subject>Gene Products, tat - immunology</subject><subject>Gene Products, tat - metabolism</subject><subject>Gene Products, tat - pharmacology</subject><subject>HIV</subject><subject>HIV infections</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - metabolism</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immune Tolerance - physiology</subject><subject>Immunoblotting</subject><subject>Immunology</subject><subject>Immunosuppression</subject><subject>Leukocytes, Mononuclear - immunology</subject><subject>Leukocytes, Mononuclear - metabolism</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - immunology</subject><subject>Macrophages - metabolism</subject><subject>Membrane Glycoproteins - antagonists & inhibitors</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Monocytes</subject><subject>Proteins</subject><subject>Recombinant Proteins - pharmacology</subject><subject>T lymphocytes</subject><subject>T-Lymphocytes, Helper-Inducer - drug effects</subject><subject>tat Gene Products, Human Immunodeficiency Virus</subject><subject>Tetanus</subject><subject>Vaccination</subject><subject>Viruses</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1v1DAUxC0EokvhjjhAxAFxyfL8kdiWuFQrYFcqgkPhajmO02aV2KntrOh_j7e7VC0HOFn2_Gbk9wahlxiWGDj9MDkdl7JeYpnvgpFHaIFB4rJmEh6jBQDhZX5mJ-hZjFsAkJWAp-gEAxOVxHSB1t-Dd352xrbFmZmTLTbjODsf52kKNsbeu6J3xa7f-eKrbXudMtjcFOvNz-JCp2J1pYfBukv7HD3p9BDti-N5in58_nSxWpfn375sVmfnpakISyVpCNCGU9E0bV0R2hlGGWeiJZ3tqqqWnIiWVjUVWW1BMyullhQLbozBpKWn6OMhd5qb0bbGuhT0oKbQjzrcKK979VBx_ZW69DuFueSQ7e-O9uCvZxuTGvto7DBoZ_0cFQdgTAj5XxBzBpzdJr79C9z6Obi8A0UAU5GHwRmCA2SCjzHY7u7DGNS-SrWvUslaYaluq8yW1_cHvWc4dJeBN0dgb_0jP4x4_29CdfMwJPsrZfTVAd3G5MMdm1fBgP4G6gi7Eg</recordid><startdate>19990914</startdate><enddate>19990914</enddate><creator>Cohen, Sandra S.</creator><creator>Li, Chiang</creator><creator>Ding, Linna</creator><creator>Cao, Yunzhen</creator><creator>Pardee, Arthur B.</creator><creator>Shevach, Ethan M.</creator><creator>Cohen, David I.</creator><general>National Academy of Sciences of the United States of America</general><general>National Acad Sciences</general><general>National Academy of Sciences</general><general>The National Academy of Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19990914</creationdate><title>Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge</title><author>Cohen, Sandra S. ; Li, Chiang ; Ding, Linna ; Cao, Yunzhen ; Pardee, Arthur B. ; Shevach, Ethan M. ; Cohen, David I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-2b203b738bbd6523fc434748d2fef5569728d35638652d0a4e99a93187ccc12d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>AIDS Vaccines - metabolism</topic><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Biological Sciences</topic><topic>Cells, Cultured</topic><topic>Disease</topic><topic>Dose-Response Relationship, Drug</topic><topic>Fas antigen</topic><topic>Fas Ligand Protein</topic><topic>FasL protein</topic><topic>Flow Cytometry</topic><topic>Gene Products, tat - immunology</topic><topic>Gene Products, tat - metabolism</topic><topic>Gene Products, tat - pharmacology</topic><topic>HIV</topic><topic>HIV infections</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - metabolism</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immune Tolerance - physiology</topic><topic>Immunoblotting</topic><topic>Immunology</topic><topic>Immunosuppression</topic><topic>Leukocytes, Mononuclear - immunology</topic><topic>Leukocytes, Mononuclear - metabolism</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - immunology</topic><topic>Macrophages - metabolism</topic><topic>Membrane Glycoproteins - antagonists & inhibitors</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Monocytes</topic><topic>Proteins</topic><topic>Recombinant Proteins - pharmacology</topic><topic>T lymphocytes</topic><topic>T-Lymphocytes, Helper-Inducer - drug effects</topic><topic>tat Gene Products, Human Immunodeficiency Virus</topic><topic>Tetanus</topic><topic>Vaccination</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Sandra S.</creatorcontrib><creatorcontrib>Li, Chiang</creatorcontrib><creatorcontrib>Ding, Linna</creatorcontrib><creatorcontrib>Cao, Yunzhen</creatorcontrib><creatorcontrib>Pardee, Arthur B.</creatorcontrib><creatorcontrib>Shevach, Ethan M.</creatorcontrib><creatorcontrib>Cohen, David I.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Sandra S.</au><au>Li, Chiang</au><au>Ding, Linna</au><au>Cao, Yunzhen</au><au>Pardee, Arthur B.</au><au>Shevach, Ethan M.</au><au>Cohen, David I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>1999-09-14</date><risdate>1999</risdate><volume>96</volume><issue>19</issue><spage>10842</spage><epage>10847</epage><pages>10842-10847</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with soluble protein (sTat), and in seroconverting humans, and propose that Tat-induced suppression cripples immune surveillance to HIV infection. We show that macrophages are sensitive to sTat stimulation at concentrations 1,000-fold lower (500 pM) than T cells, and this stimulation is accompanied by the immunosuppressive induction of Fas ligand on the macrophage. T cell proliferative defects induced by sTat in vitro can be completely (at lower concentrations of sTat) or partially (at higher concentrations) reversed by antagonists to Fas/Fas ligand interaction. We further report a method to preserve immunogenicity while inactivating Tat immunosuppression through oxidation, which advances the use of oxidized Tat as a component of an anti-HIV vaccine. These observations define additional methods to study the immunosuppressive functions of sTat that now may be rapidly applied to primary isolates from individuals with differing clinical courses. Our findings have immediate relevance for vaccine development, by describing and supporting a strategy that includes inactivated sTat in a multicomponent, anti-HIV vaccine.</abstract><cop>United States</cop><pub>National Academy of Sciences of the United States of America</pub><pmid>10485913</pmid><doi>10.1073/pnas.96.19.10842</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0027-8424 |
ispartof | Proceedings of the National Academy of Sciences - PNAS, 1999-09, Vol.96 (19), p.10842-10847 |
issn | 0027-8424 1091-6490 |
language | eng |
recordid | cdi_proquest_journals_201383561 |
source | MEDLINE; Jstor Complete Legacy; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
subjects | AIDS Vaccines - metabolism AIDS/HIV Animals Antibodies Antigens Biological Sciences Cells, Cultured Disease Dose-Response Relationship, Drug Fas antigen Fas Ligand Protein FasL protein Flow Cytometry Gene Products, tat - immunology Gene Products, tat - metabolism Gene Products, tat - pharmacology HIV HIV infections HIV Infections - immunology HIV Infections - metabolism Human immunodeficiency virus Humans Immune Tolerance - physiology Immunoblotting Immunology Immunosuppression Leukocytes, Mononuclear - immunology Leukocytes, Mononuclear - metabolism Macrophages - drug effects Macrophages - immunology Macrophages - metabolism Membrane Glycoproteins - antagonists & inhibitors Membrane Glycoproteins - metabolism Mice Mice, Inbred BALB C Monocytes Proteins Recombinant Proteins - pharmacology T lymphocytes T-Lymphocytes, Helper-Inducer - drug effects tat Gene Products, Human Immunodeficiency Virus Tetanus Vaccination Viruses |
title | Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T01%3A58%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pronounced%20Acute%20Immunosuppression%20in%20vivo%20Mediated%20by%20HIV%20Tat%20Challenge&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Cohen,%20Sandra%20S.&rft.date=1999-09-14&rft.volume=96&rft.issue=19&rft.spage=10842&rft.epage=10847&rft.pages=10842-10847&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.96.19.10842&rft_dat=%3Cjstor_proqu%3E48840%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201383561&rft_id=info:pmid/10485913&rft_jstor_id=48840&rfr_iscdi=true |